Trial Profile
Prospective Phase II Study of Decitabine Induction Therapy to Reduce Pre-transplant Disease Burden Prior to Allogeneic Hematopoietic Cell Transplant in Patients With Newly Diagnosed Myelodysplastic Syndromes.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 25 Jul 2014
Price :
$35
*
At a glance
- Drugs Decitabine (Primary)
- Indications Myelodysplastic syndromes
- Focus Therapeutic Use
- 16 Jun 2014 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 15 Apr 2011 New trial record